Gyre Therapeutics (GYRE) Change in Accured Expenses (2010 - 2026)

Gyre Therapeutics (GYRE) has reported Change in Accured Expenses for 17 consecutive years, with $683000.0 the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Accured Expenses fell 84.62% year-over-year to $683000.0; the TTM figure through Mar 2026 stood at -$2.8 million (down 157.26% YoY), while the FY2025 annual figure was $946000.0, up 163.19% from the prior year.
• Change in Accured Expenses fell to $683000.0 in Q1 2026 per GYRE's latest filing, from $2.4 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $6.2 million in Q4 2022 and bottomed at -$4.7 million in Q2 2022.
• Historically, Change in Accured Expenses has averaged $205411.8 across 5 years, with a median of $683000.0 in 2026.
• Annual changes were most pronounced in 2022 — Change in Accured Expenses surged 3441.94% — and 2025, when it tumbled 3275.71%.
• Gyre Therapeutics' Change in Accured Expenses stood at $6.2 million in 2022, then sank by 76.06% to $1.5 million in 2023, then soared by 39.95% to $2.1 million in 2024, then climbed by 13.98% to $2.4 million in 2025, then tumbled by 71.3% to $683000.0 in 2026.
• Business Quant data shows GYRE's Change in Accured Expenses at $683000.0 in Q1 2026, $2.4 million in Q4 2025, and -$3.5 million in Q3 2025.